BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

173 related articles for article (PubMed ID: 32565109)

  • 1. Clinical Features and Survival of Single Hormone Receptor-Positive Breast Cancer: A Population-Based Study of 531,605 Patients.
    Lv M; Mao Y; Song Y; Wang Y; Liu X; Wang X; Nie G; Wang H
    Clin Breast Cancer; 2020 Oct; 20(5):e589-e599. PubMed ID: 32565109
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Poor prognosis of single hormone receptor- positive breast cancer: similar outcome as triple-negative breast cancer.
    Bae SY; Kim S; Lee JH; Lee HC; Lee SK; Kil WH; Kim SW; Lee JE; Nam SJ
    BMC Cancer; 2015 Mar; 15():138. PubMed ID: 25880075
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinicopathological Characteristics and Breast Cancer-Specific Survival of Patients With Single Hormone Receptor-Positive Breast Cancer.
    Li Y; Yang D; Yin X; Zhang X; Huang J; Wu Y; Wang M; Yi Z; Li H; Li H; Ren G
    JAMA Netw Open; 2020 Jan; 3(1):e1918160. PubMed ID: 31899528
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Combined Estrogen Receptor and Progesterone Receptor Level Can Predict Survival Outcome in Human Epidermal Growth Factor Receptor 2-positive Early Breast Cancer.
    Chen M; Wu J; Liu D; Chen W; Lin C; Andriani L; Ding S; Huang O; He J; Chen X; Chen W; Li Y; Shen K; Zhu L
    Clin Breast Cancer; 2022 Feb; 22(2):e147-e156. PubMed ID: 34244052
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Single Hormone Receptor-Positive Metaplastic Breast Cancer: Similar Outcome as Triple-Negative Subtype.
    Mao J; Hu J; Zhang Y; Shen J; Dong F; Zhang X; Ming J; Huang T; Run X
    Front Endocrinol (Lausanne); 2021; 12():628939. PubMed ID: 33972826
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Early and Locally Advanced Metaplastic Breast Cancer: Presentation and Survival by Receptor Status in Surveillance, Epidemiology, and End Results (SEER) 2010-2014.
    Schroeder MC; Rastogi P; Geyer CE; Miller LD; Thomas A
    Oncologist; 2018 Apr; 23(4):481-488. PubMed ID: 29330212
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Hormone receptor-negative breast cancer: undertreatment of patients over 80.
    Weiss A; Noorbakhsh A; Tokin C; Chang D; Blair SL
    Ann Surg Oncol; 2013 Oct; 20(10):3274-8. PubMed ID: 23838924
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Breast Cancer Survival Analysis Based on Immunohistochemistry Subtypes (ER/PR/HER2): a Retrospective Cohort Study.
    Poorolajal J; Nafissi N; Akbari ME; Mahjub H; Esmailnasab N; Babaee E
    Arch Iran Med; 2016 Oct; 19(10):680-686. PubMed ID: 27743431
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Distinct ER and PR expression patterns significantly affect the clinical outcomes of early HER2-positive breast cancer: A real-world analysis of 871 patients treated with neoadjuvant therapy.
    Chen H; Gui X; Zhou Z; Su F; Gong C; Li S; Wu W; Rao N; Liu Q; Yao H
    Breast; 2024 Jun; 75():103733. PubMed ID: 38615482
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinical Characteristics and Outcomes of Single Versus Double Hormone Receptor-Positive Breast Cancer in 2 Large Databases.
    Li Z; Tu Y; Wu Q; Wang Z; Li J; Zhang Y; Sun S
    Clin Breast Cancer; 2020 Apr; 20(2):e151-e163. PubMed ID: 31551181
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinicopathological differences and survival benefit in ER+/PR+/HER2+ vs ER+/PR-/HER2+ breast cancer subtypes.
    Ding W; Ye D; Chen H; Lin Y; Li Z; Tu C
    Breast Cancer; 2024 Mar; 31(2):295-304. PubMed ID: 38231460
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Adjuvant chemotherapy could not bring survival benefit to HR-positive, HER2-negative, pT1b-c/N0-1/M0 invasive lobular carcinoma of the breast: a propensity score matching study based on SEER database.
    Hu G; Hu G; Zhang C; Lin X; Shan M; Yu Y; Lu Y; Niu R; Ye H; Wang C; Xu C
    BMC Cancer; 2020 Feb; 20(1):136. PubMed ID: 32085753
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Do clinical features and survival of single hormone receptor positive breast cancers differ from double hormone receptor positive breast cancers?
    Ng CH; Pathy NB; Taib NA; Ho GF; Mun KS; Rhodes A; Looi LM; Yip CH
    Asian Pac J Cancer Prev; 2014; 15(18):7959-64. PubMed ID: 25292095
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A population-based study of Kurdish breast cancer in northern Iraq: hormone receptor and HER2 status. A comparison with Arabic women and United States SEER data.
    Runnak MA; Hazha MA; Hemin HA; Wasan AA; Rekawt RM; Michael HD
    BMC Womens Health; 2012 Jun; 12():16. PubMed ID: 22727195
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The Prognosis and Predictive Value of Estrogen Negative/Progesterone Positive (ER-/PR+) Phenotype: Experience of 1159 Primary Breast Cancer from a Single Institute.
    Gamrani S; Boukansa S; Benbrahim Z; Mellas N; Fdili Alaoui F; Melhouf MA; Bouchikhi C; Banani A; Boubbou M; Bouhafa T; El Fatemi H
    Breast J; 2022; 2022():9238804. PubMed ID: 35711896
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Breast Cancer Outcomes as Defined by the Estrogen Receptor, Progesterone Receptor, and Human Growth Factor Receptor-2 in a Multi-ethnic Asian Country.
    Subramaniam S; Bhoo-Pathy N; Taib NA; Tan GH; See MH; Jamaris S; Ho GF; Looi LM; Yip CH
    World J Surg; 2015 Oct; 39(10):2450-8. PubMed ID: 26138872
    [TBL] [Abstract][Full Text] [Related]  

  • 17. HER2 status and disparities in luminal breast cancers.
    Holowatyj AN; Ruterbusch JJ; Ratnam M; Gorski DH; Cote ML
    Cancer Med; 2016 Aug; 5(8):2109-16. PubMed ID: 27250116
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The hormone receptor status in breast cancer and the relationship of subtypes with clinicopathological features.
    Senel F
    Indian J Pathol Microbiol; 2021; 64(4):671-676. PubMed ID: 34673584
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Breast cancer subtypes as defined by the estrogen receptor (ER), progesterone receptor (PR), and the human epidermal growth factor receptor 2 (HER2) among women with invasive breast cancer in California, 1999-2004.
    Parise CA; Bauer KR; Brown MM; Caggiano V
    Breast J; 2009; 15(6):593-602. PubMed ID: 19764994
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Breast cancer-specific survival by clinical subtype after 7 years follow-up of young and elderly women in a nationwide cohort.
    Johansson ALV; Trewin CB; Hjerkind KV; Ellingjord-Dale M; Johannesen TB; Ursin G
    Int J Cancer; 2019 Mar; 144(6):1251-1261. PubMed ID: 30367449
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.